Saturday, February 21, 2026
18.4 C
Bengaluru

Opportunities for Indian Pharma

[wpfilebase tag=file id=75 tpl=download-button /]

Inside this Issue

1. Medical Rep to Country Head by Bhaskar Chakravorti
Bhaskar Chakravorti – Vice President, Micro Labs, talks about the growth of his career and his love for the country he presently calls ‘home’.

2. “Organizational Alignment Begins with a Common Vocabulary” by Hanno Wolfram
Our Editor Anup Soans sits down for a tête-à-tête with Hanno Wolfram – Owner, Innov8 and Member, MedicinMan Editorial Board.

3. Motivation: The No. 1 Challenge for Frontline Managers by K. Hariram
Motivation is created in teams only when ‘people’ and ‘purpose’ are prioritised.

4. A Pharma Technology Company Deeply Rooted in Experience by Krishna Singh
Krishna Singh spent 15 years in the Pharma Industry, beginning as a Medical Rep, before starting GlobalSpace technologies – a real Pharma field force multiplier.

5. Is Pharma Brand Management Promoting Mediocrity? by Shreenivas S
Simply hiring people because they have MBAs, without ascertaining their domain expertise or competency for the job, is a sure recipe for disaster. .

6. To Survive in the Jungle of Pharma Sales, Think like a Lion? by Chandan Kumar
Simple pointers to survive and thrive in the jungle of pharma sales.

7. Indian Pharma’s Many Challenges by Salil Kallianpur
The Indian Pharma Industry faces a multitude of challenges (and opportunities), some of which are unique to different sets of players, such as domestic Co’s and MNCs.

Hot this week

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich

When a new cancer drug shows promise, it trends...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Topics

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...

Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?

Transparency, Trust, and the Problem of “Invisible Evidence” in...
spot_img

Related Articles

spot_imgspot_img